Tuesday, March 31, 2020

Biocon#39;s insulin manufacturing facility in Malaysia gets EIR with VAI classification From USFDA

Biocon#39;s insulin manufacturing facility in Malaysia gets EIR with VAI classification From USFDA In a regulatory filing the company said, Biocon Sdn Bhd, a subsidiary of Biocon Ltd has received the EIR from the USFDA for the Pre-Approval Inspection (PAI) of its insulin manufacturing facility in Malaysia, for Insulin Glargine.

from Moneycontrol Business News https://ift.tt/3azKKTG
at
Labels: , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Wipro guides for revenue of (-) 1.5% to 0.5% in Q1FY25

CFO Aparna Iyer said it is a tough macroeconomic environment and clients are going through a very challenging time. from Moneycontrol Bus...